|
US6544769B1
(en)
*
|
1996-12-13 |
2003-04-08 |
Schering Corporation |
Compostions comprising viruses and methods for concentrating virus preparations
|
|
US20080261289A1
(en)
*
|
1996-12-13 |
2008-10-23 |
Schering-Plough Corporation |
Compositions comprising viruses and methods for concentrating virus preparations
|
|
WO2000032233A2
(en)
*
|
1998-12-03 |
2000-06-08 |
Avigen, Inc. |
Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
|
|
US6759050B1
(en)
|
1998-12-03 |
2004-07-06 |
Avigen, Inc. |
Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
|
|
US6225289B1
(en)
*
|
1998-12-10 |
2001-05-01 |
Genvec, Inc. |
Methods and compositions for preserving adenoviral vectors
|
|
FR2791999B1
(fr)
*
|
1999-04-09 |
2001-09-07 |
Aventis Pharma Sa |
Composition destinee a la conservation d'adenovirus recombinants infectieux
|
|
JP2002541792A
(ja)
*
|
1999-04-09 |
2002-12-10 |
アベンテイス・フアルマ・ソシエテ・アノニム |
感染性の組換えアデノウイルスの保存用組成物
|
|
US7456009B2
(en)
|
2000-03-07 |
2008-11-25 |
Merck & Co., Inc. |
Adenovirus formulations
|
|
JP5118798B2
(ja)
*
|
2000-03-07 |
2013-01-16 |
メルク・シャープ・エンド・ドーム・コーポレイション |
アデノウイルス製剤
|
|
WO2001085928A1
(en)
*
|
2000-05-10 |
2001-11-15 |
Mitsubishi Pharma Corporation |
Method of preparing virus vector
|
|
WO2003049763A1
(en)
|
2001-12-12 |
2003-06-19 |
Fh Faulding & Co Limited |
Composition for the preservation of viruses
|
|
JP2005515245A
(ja)
*
|
2002-01-18 |
2005-05-26 |
シエーリング アクチエンゲゼルシャフト |
アデノウィルスの安定化された配合物
|
|
KR100507794B1
(ko)
*
|
2003-02-11 |
2005-08-17 |
한미약품 주식회사 |
고농도 레트로 바이러스 현탁액 제조 방법
|
|
US20070148765A1
(en)
*
|
2003-11-19 |
2007-06-28 |
Evans Robert K |
Preservative-containing virus formulations
|
|
ES2329607T3
(es)
*
|
2004-02-23 |
2009-11-27 |
Crucell Holland B.V. |
Metodos de purificacion de virus.
|
|
GB0502661D0
(en)
*
|
2005-02-09 |
2005-03-16 |
Stabilitech Ltd |
A desiccated product
|
|
AU2006233800B2
(en)
*
|
2005-04-11 |
2011-07-07 |
Crucell Holland B.V. |
Virus purification using ultrafiltration
|
|
CN1961961B
(zh)
*
|
2005-11-11 |
2010-05-26 |
深圳市源兴生物医药科技有限公司 |
一种药物制剂及其制备方法
|
|
BRPI0921651A2
(pt)
|
2008-11-03 |
2015-08-18 |
Crucell Holland Bv |
Método para produzir adenovírus recombinante, e partículas virais, e, biorreator
|
|
JP5250155B2
(ja)
|
2010-02-15 |
2013-07-31 |
クルセル ホランド ベー ヴェー |
Ａｄ２６アデノウイルスベクターの製造方法
|
|
WO2012038367A1
(en)
|
2010-09-20 |
2012-03-29 |
Crucell Holland B.V. |
Therapeutic vaccination against active tuberculosis
|
|
MX354752B
(es)
|
2010-09-27 |
2018-03-20 |
Janssen Vaccines & Prevention Bv |
Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
|
|
TW201233802A
(en)
|
2010-12-02 |
2012-08-16 |
Oncolytics Biotech Inc |
Liquid viral formulations
|
|
WO2012075376A2
(en)
|
2010-12-02 |
2012-06-07 |
Oncolytics Biotech Inc. |
Lyophilized viral formulations
|
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
KR102044051B1
(ko)
|
2012-03-12 |
2019-11-12 |
얀센 백신스 앤드 프리벤션 비.브이. |
터미널 말단이 변경된 재조합 아데노바이러스의 배치
|
|
AU2013237429B2
(en)
|
2012-03-22 |
2015-07-23 |
Crucell Holland B.V. |
Vaccine against RSV
|
|
US9119813B2
(en)
|
2012-03-22 |
2015-09-01 |
Crucell Holland B.V. |
Vaccine against RSV
|
|
WO2014009433A1
(en)
|
2012-07-10 |
2014-01-16 |
Transgene Sa |
Mycobacterium resuscitation promoting factor for use as adjuvant
|
|
EP2872172B1
(en)
|
2012-07-10 |
2018-11-14 |
Transgene SA |
Mycobacterial antigen vaccine
|
|
EA035522B1
(ru)
|
2013-04-25 |
2020-06-29 |
Янссен Вэксинс Энд Превеншн Б.В. |
Стабильные растворимые f-полипептиды rsv в конформации "до слияния"
|
|
JP6679475B2
(ja)
|
2013-06-17 |
2020-04-15 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
安定化された可溶性融合前ｒｓｖ ｆポリペプチド
|
|
JP6605480B2
(ja)
|
2014-01-09 |
2019-11-13 |
トランスジェン・ソシエテ・アノニム |
ヘテロオリゴマーマイコバクテリア抗原の融合物
|
|
US9721484B2
(en)
|
2014-06-23 |
2017-08-01 |
Humanetics Innovative Solutions, Inc. |
Shoulder kit assembly for crash test dummy
|
|
RU2696312C2
(ru)
|
2014-07-16 |
2019-08-01 |
Трансген Са |
Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
|
|
US10008130B2
(en)
|
2014-09-17 |
2018-06-26 |
Humanetics Innovative Solutions, Inc. |
Omni-directional shoulder assembly for crash test dummy
|
|
WO2016128542A1
(en)
|
2015-02-13 |
2016-08-18 |
Transgene Sa |
Immunotherapeutic vaccine and antibody combination therapy
|
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
|
WO2016166088A1
(en)
|
2015-04-14 |
2016-10-20 |
Janssen Vaccines & Prevention B.V. |
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
|
|
JP6840718B2
(ja)
|
2015-07-07 |
2021-03-10 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
安定化された可溶性融合前ｒｓｖ ｆポリペプチド
|
|
US10456462B2
(en)
|
2015-07-07 |
2019-10-29 |
Janssen Vaccines & Preventions B.V. |
Vaccine against RSV
|
|
US10729757B2
(en)
|
2016-04-05 |
2020-08-04 |
Janssen Vaccines & Prevention B.V. |
Vaccine against RSV
|
|
AU2017248021B2
(en)
|
2016-04-05 |
2021-08-12 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F proteins
|
|
WO2017194655A1
(en)
|
2016-05-12 |
2017-11-16 |
Janssen Vaccines & Prevention B.V. |
Potent and balanced bidirectional promoter
|
|
DK3464331T3
(da)
|
2016-05-30 |
2021-01-18 |
Janssen Vaccines & Prevention Bv |
Stabiliserede præfusions-rsv f-proteiner
|
|
CN109312362B
(zh)
|
2016-06-20 |
2022-06-28 |
扬森疫苗与预防公司 |
有效和平衡的双向启动子
|
|
WO2018011196A1
(en)
|
2016-07-14 |
2018-01-18 |
Janssen Vaccines & Prevention B.V. |
Hpv vaccines
|
|
TW201825674A
(zh)
|
2016-09-09 |
2018-07-16 |
美商艾斯合顧問有限公司 |
表現雙特異性接合分子的溶瘤病毒
|
|
WO2018091680A1
(en)
|
2016-11-18 |
2018-05-24 |
Transgene Sa |
Cowpox-based oncolytic vectors
|
|
JP7110203B2
(ja)
|
2016-12-28 |
2022-08-01 |
トランジェーヌ |
腫瘍溶解性ウイルスおよび治療用分子
|
|
JP6721797B2
(ja)
|
2017-02-09 |
2020-07-15 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
異種遺伝子発現のための強力で短いプロモーター
|
|
EP3624844A1
(en)
|
2017-05-17 |
2020-03-25 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
|
WO2018210871A1
(en)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
|
WO2019020543A1
(en)
|
2017-07-28 |
2019-01-31 |
Transgene Sa |
ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
|
|
CN111163800A
(zh)
|
2017-09-15 |
2020-05-15 |
扬森疫苗与预防公司 |
用于安全诱导针对rsv的免疫的方法
|
|
WO2020011754A1
(en)
|
2018-07-09 |
2020-01-16 |
Transgene |
Chimeric vaccinia viruses
|
|
JP7557738B2
(ja)
|
2018-10-30 |
2024-09-30 |
国立大学法人 東京大学 |
がん治療のための腫瘍溶解性ウイルス
|
|
KR20210091749A
(ko)
|
2018-11-13 |
2021-07-22 |
얀센 백신스 앤드 프리벤션 비.브이. |
안정화된 융합전 rsv f 단백질
|
|
KR20220134622A
(ko)
|
2020-01-31 |
2022-10-05 |
베쓰 이스라엘 디코니스 메디칼 센터 인크 |
코로나바이러스 감염 예방 및 치료용 조성물 및 방법 - sars-cov-2 백신
|
|
IL296520A
(en)
|
2020-03-19 |
2022-11-01 |
Trizell Ltd |
Temperature-responsive virus storage system
|
|
US20230256057A1
(en)
|
2020-07-13 |
2023-08-17 |
Transgene |
Treatment of immune depression
|
|
IL304904A
(en)
|
2021-02-01 |
2023-10-01 |
St Phi Therapeutics Co Ltd |
Target protein degradation system and its use
|
|
MX2023009738A
(es)
|
2021-02-19 |
2023-08-30 |
Janssen Vaccines & Prevention Bv |
Antigenos de rsv fb prefusion estabilizados.
|
|
WO2023020939A1
(en)
|
2021-08-17 |
2023-02-23 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
WO2023025899A2
(en)
|
2021-08-26 |
2023-03-02 |
Transgene |
Delivery system for targeting genes of the interferon pathway
|
|
WO2023111725A1
(en)
|
2021-12-14 |
2023-06-22 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
|
CN119654339A
(zh)
|
2022-07-01 |
2025-03-18 |
特兰斯吉恩股份有限公司 |
包含表面活性蛋白-d和tnfsf成员的融合蛋白
|
|
EP4573113A1
(en)
|
2022-08-18 |
2025-06-25 |
Transgene |
Chimeric poxviruses
|